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Abstract 
Abstract 
Background: Guidelines recommend that patients at risk of anaphylaxis are given an anaphylaxis 
management plan (AMP) providing advice on symptom recognition and emergency management.  
However, the format and content of plans is not standardised.  
 
Objective: To review the design and contents of different AMPs available in English.   
 
Methods:  A systematic internet search identified AMPs published online. Each plan was analysed for 
design and content (including signs and symptoms indicative of anaphylaxis and the actions to be 
taken). The content was compared with a Delphi derived statement of the key characteristics of an 
AMP. 
 
Results: The systematic search identified 41 plans from 29 different sources. The majority of plans 
identified were personalised management plans for individuals (78%), the others were designed for 
institutions. Most AMPs addressed both mild/moderate and severe allergic reactions and had different 
instructions related to the degree of severity. Thirty seven individual symptoms were mentioned as 
indicators of anaphylaxis. Only 55% of plans that recommended the administration of an adrenaline 
auto-injector gave further instructions on how to do this. Only 17% of plans contained comprehensive 
instructions on safe patient positioning. 
 
Conclusions: There are a wide variety of AMPs in English available online. Plans are similar in design, 
but differ in content. None of the currently available plans contain all the desirable components 
recommended in the literature. Because of the variation between plans, when practitioners are 
selecting an AMP for their patient they need to be attentive to the content of the plan and its 
appropriateness for that individual. 
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What is already known about this topic? 
Anaphylaxis management plans (AMPs) are recommended for all patients in international 
guidelines and there are a number of plans published globally. Past research has 
recommended components to be included in AMPs. 
What does this article add to our knowledge? 
Forty-one plans were identified and had their design and content catalogued. No plans 
contained all previously recommended components. Other key instructions to patients were 
missing from plans regarding auto-injector usage and patient positioning. 
How does this study impact current management guidelines? 
Clinicians must be selective in choosing the optimal AMP for their patients. Clinicians should 
be aware that currently available AMPs do not include all recommended components. Future 
plans should consider including patient positioning guidance. 
 
 
Abbreviations:  
AAI Adrenaline auto-Injector 
AMP Anaphylaxis management plan 
CNS Central nervous system 
CV Cardiovascular 
EAACI European Academy of Allergy and Clinical 
Immunology 
GI Gastrointestinal 
RCPCH Royal College of Paediatrics and Child 
Health 
WAO World Allergy Organisation 
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Introduction 1 
International (e.g. WAO), regional (EAACI) and national guidelines (RCPCH) recommend 2 
patients at risk of anaphylaxis are provided with adrenaline auto injectors (AAIs) together with 3 
written instructions describing how, and when, to administer them.  Although there are many 4 
anaphylaxis management plans (AMPs) available they are not universally employed.  A survey 5 
published in 2008 reported that 64% of 1,885 patients who had suffered probable anaphylaxis 6 
in the community did not possess a written AMP.(1) 7 
Whilst there is no grade A evidence for the use of AMP, their use is supported by two case 8 
series demonstrating a reduced number of severe allergic episodes in patients provided with 9 
a written AMP as part of a wider training and education program.(2, 3) In addition the 10 
possession of a written AMP has been shown to be associated with better adherence to self-11 
care behaviours in adolescents.(4)  The ideal content of an AMP was developed in 2010 in the 12 
UK using an e-Delphi approach(5) where 26 experts in allergy were contacted for their opinions 13 
by email.  All responses were collated and then returned to the expert panel in an anonymous 14 
format.  The next stage involved voting on their agreement with each of the opinions proposed 15 
in the first round.  This study reported 12 recommended components to be included in AMPs, 16 
these were agreed by ≥80% of the panel of experts.  17 
 18 
Methods 19 
To identify AMPs a systematic search of the internet was carried out between November 2015 20 
and January 2016. The search strategy is summarised in Table OR1 in the Online Repository.  21 
Each term was searched for individually.  The first 100 results from each of the five search 22 
terms used, sorted by the search engine’s measurement of relevance, were screened for 23 
inclusion.  The initial screening identified whether the title of the web matched inclusion and 24 
exclusion criteria.  Results continued to be screened beyond 100 until ten consecutive page 25 
titles were excluded as not being relevant. 26 
Our search focused on countries where a large proportion of the population spoke English as 27 
their first language and there was a healthcare system that includes specialist allergy services:  28 
Australia, Canada, New Zealand, Republic of Ireland, South Africa, United Kingdom, and United 29 
States of America. 30 
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The most frequently visited search engine for each country was used, based on Alexa® web 31 
traffic ranking. This uses a sample of millions of internet browsers to estimate popularity.  In 32 
all seven cases the dominant search engine was the regional variant of Google® 33 
Identified websites were examined thoroughly.  Where websites had an internal search 34 
facility, this was used with the terms “anaphylaxis” and “plan” to find relevant pages. In 35 
addition to locating management plans published on identified websites, each site was 36 
searched for links or reference to websites not previously located.  In the event that a website 37 
required a username and password to access content, wherever possible an account was 38 
created and used.  If plans were located but not accessible the website administrator was 39 
contacted to request a copy. 40 
A data extraction form was designed to capture all symptoms mentioned, instructions given, 41 
and other written components in addition to design elements. The form was piloted on six 42 
plans and revised before being used to review the remaining plans.  Any unexpected 43 
characteristics encountered were noted and added to the data extraction form before the 44 
AMPs were assessed for a second time. These results were presented descriptively together 45 
with an analysis of how many of the twelve e-Delphi study recommended components were 46 
included in each AMP. 47 
 48 
  49 
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Results 50 
The systematic search identified 284 websites to review, 29 of these websites published AMPs 51 
and seven published multiple versions – resulting in 41 distinct AMPs in total. Eleven plans 52 
originated from the U.K., ten from both Canada and the U.S., four from both Australia and 53 
Ireland, and one from South Africa.  Another plan was identified from a secondary source, a 54 
website that publishes management plans in 16 different languages, including English. 55 
Information about the origin of each plan and the access details are available in Table OR2 in 56 
the Online Repository.  57 
Origins of management plans 58 
The majority of plans (24/41, 59%) were published by charities or non-governmental 59 
organisations.  Six plans (15%) were published by primary or secondary healthcare providers 60 
and six (15%) were published by education authorities or schools.  The remaining five plans 61 
(12%) were published by care providers/community organisations, pharmaceutical 62 
companies, public or regional health bodies or private individuals. 63 
Thirty-two plans (78%) were designed for an individual.  The others were to be applied to any 64 
person suffering anaphylaxis within an institution (for example, in a school setting the AMP 65 
could be used for any pupil). Sixteen plans (39%) were specifically designed to be used in 66 
schools. The 32 plans (78%) for individuals contained space to record a range of variables 67 
about the patient.  The prevalence of these is shown in Table i. 68 
Twenty-four plans (59%) included a year of publication. Nine (22%) were published in 2014-69 
2015, eight (20%) between 2012-2013, five (12%) between 2010 and 2011 and the remaining 70 
two (5%) in 2009.  Only seven plans (17%) included any indication of version number. 71 
Design 72 
The plans were all A4 or Letter sized, 24 (59%) were single side, whilst 15 (37%) were two sides 73 
in length.  Two plans were longer, covering four and five sides respectively. 74 
The plans commonly featured logos and visuals demonstrating auto injection, but only two 75 
plans (5%) used other graphics.  Nineteen plans (46%) were published in full colour versus 76 
greyscale.  The mean word count was 453 words (range: 183 – 1,664), with plans designed for 77 
individuals containing fewer words than plans designed for institutions (p=0.048).  The mean 78 
word count per page was 327 words (range: 199-1664) with plans designed for institutions 79 
having more words per page (p=0.013).   80 
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Information recorded about the plan and the patient 81 
Advice on preventing anaphylaxis 82 
 Seventeen plans (41%) contained information aimed at reducing the risk of anaphylaxis or 83 
instructions on what to carry in anticipation of a reaction.  These instructions are shown in 84 
Table ii.  Four plans, all of which were designed for institutions, contained more detailed 85 
instructions for the day-to-day management of at-risk individuals as well as emergency 86 
management plans.   87 
Symptoms discussed 88 
Across all plans a total of 37 distinct symptoms or signs relating to anaphylaxis were 89 
mentioned. These could be categorised by systems; central nervous system (CNS), 90 
cardiovascular (CV), gastrointestinal (GI), respiratory system, dermatological and other. 91 
The most frequently mentioned symptom category across all plans were respiratory, followed 92 
by GI or dermatological effects. 93 
Frequently plans made some distinction between signs or symptoms that were indicative of a 94 
mild/moderate and those that were severe, and recommended different actions accordingly 95 
(26, 63%).  Two plans (5%) advised that multiple mild symptoms from more than one body 96 
system should be considered a severe reaction.  Fifteen symptoms (37%) were classified as 97 
mild in some plans and severe in others.  These symptoms were mapped to the grading system 98 
published by the WAO for subcutaneous immunotherapy reactions(6).  This system attempts 99 
to grade reactions into four groups of increasing severity.  Of the 37 identified symptoms in 100 
AMPs, 23 are included in the WAO grading system.  Those that were not explicitly included 101 
related to young children or were symptomatic manifestations of underlying pathology (for 102 
example ‘dizziness’ in our data would probably be included in “Hypotension with or without 103 
loss of consciousness” in the WAO grading).  This reflects the difference in target audience; 104 
AMPs are designed for lay people whilst the WAO system is for health professionals.   105 
 106 
The overall prevalence and severity classification for each symptom identified is recorded in 107 
Figure 2.  This shows that there was broad agreement between AMPs as to which symptoms 108 
considered mild and which severe. The classification of severity closely reflected the WAO 109 
grading of severity, with a few exceptions.  These were nausea and vomiting (normally 110 
considered mild in AMPs, classified as a grade 2 reaction in the WAO system) and coughing 111 
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(considered Grade 1 in the WAO system but considered severe in all plans that made the 112 
distinction between mild and severe).   113 
Three plans (7%) contained space for patients to record additional symptoms if they 114 
experienced symptoms of anaphylaxis not already listed. 115 
The trigger for action varied between plans.  In 18 plans (44%) patients were instructed to take 116 
action if they recognised any one severe symptom.  Nine plans (22%) advised patients to 117 
monitor for worsening symptoms, with the same number cautioning that symptom 118 
progression may be rapid.  Four plans, from Australasia and South Africa, gave specific 119 
information for insect allergic patients - upgrading mild GI symptoms to severe. 120 
The mean number of symptoms mentioned per plan was 19 (range: 11-27). 121 
Actions to take 122 
Actions to be taken in the event of an allergic reaction were varied, but fell broadly into two 123 
categories: direct instructions to the patient or bystander and supporting information.  The 124 
prevalence of these instructions and information supporting them are recorded in Table iii. 125 
Half of all plans (51%) recommended giving antihistamines. All plans recommended that when 126 
symptoms indicated a severe reaction an ambulance should be called.  Plans recommending 127 
a second dose of adrenaline varied in recommended interval between injections.  Fifteen 128 
plans (50%) recommended 5 minutes, 14 (47%) gave a range of between 5-15 minutes, whilst 129 
one plan advised after “a few minutes or more”. 130 
Additional supporting information printed on plans included the ambulance phone number 131 
for the relevant geographic area, a recommendation for transport to hospital for further 132 
observation and reassurance to patients/bystanders that if there is doubt it is better to use 133 
the AAI than not. 134 
Eight plans (20%) advised taking a second dose of any medications vomited.  One plan gave 135 
opposing advice, instructing patients and bystanders not to repeat the dose if the patient 136 
vomits.  137 
Three plans provided a section for the recording of the allergens a patient is “extremely 138 
reactive” to, two advised that an AAI be administered for any one symptom mentioned in this 139 
case.  All three of these plans also advised that an AAI be used after any possible exposure to 140 
an extremely reactive allergen even if the patient is not symptomatic.  141 
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Auto-injector instructions 142 
Thirty-eight plans (93%) contained an instruction to administer an AAI to the patient.  Two of 143 
the plans that did not contain this instruction were U.K. plans designed for patients not 144 
prescribed an AAI.  One, however, was   an institutional anaphylaxis plan for school use in the 145 
United States. 146 
Despite the high proportion of AMPs instructing patients to administer an AAI, only 55% of 147 
plans that mandated the delivery of the injection included any instructions on how to do so. 148 
Instructions were identified for nine individual types of AAI, in addition to instructions for 149 
using drawing up adrenaline from a vial using a needle and syringe (see Online Repository 150 
Figure 1). 151 
Five plans gave instructions for different brands in one document. 152 
Asthma advice 153 
Fifteen plans (37%) had the option to record asthma explicitly available, whilst 12 (29%) 154 
contained space to record details of asthma medication. 155 
Within the actions to take section of plans, 16 plans (39%) instructed responders to give 156 
asthma inhalers.  Five plans (12%) instructed responders to deliver an AAI if they were unsure 157 
whether the patient was having an asthmatic or anaphylactic attack. 158 
Miscellaneous 159 
The facility to record the brand and dosage of AAI device prescribed was infrequently included 160 
AMPs, appearing in 11 (27%) and 13 (32%) plans respectively.  Space to record the expiry date 161 
of the device was rare, being found in only two plans (5%). 162 
Some plans were adapted for children.  Three plans (7%) recorded whether a child was capable 163 
of self-administering and two (5%) provided information on whether the child carried their 164 
AAI on their person.  A further two plans (5%) gave details of staff members who have received 165 
training in anaphylaxis management.   Three plans (7%) gave advice on what to document 166 
after an anaphylactic episode.  167 
Presence of recommended components 168 
No plan included all of the items recommended by experts participating in the consensus e-169 
Delphi study.(5)  The most commonly omitted elements were  where the medication is stored, 170 
the review and expiry dates of medications, the number of AAIs to be carried and a list of who 171 
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in the patient’s environment is trained to use them.  The median number of recommended 172 
components present in the plans reviewed was four, from a maximum of ten possible. 173 
The plan that came closest to including all of the recommended features was a plan designed 174 
for institutions published by Northcott, an Australian not-for-profit disability care provider 175 
(plan no. 39, table OR2); this included nine out of ten recommendations. There was also a plan 176 
containing eight of the recommended components, this was also intended for institutional use 177 
and published by the Illinois State Board of Education (plan no. 32).  Each recommended 178 
component from the e-Delphi study is listed and cross referenced against the plans we 179 
identified in table OR3 in the online repository.  180 
Discussion 181 
We found 41 different management plans, all of broadly similar designs: text based 182 
instructions formatted as bullet points, often within one or two sides of A4 paper.  This reflects 183 
their need to contain quickly accessible information in an emergency.  The majority are 184 
designed for individuals.  Others are designed for institutions, for example schools.  Most plans 185 
were clearly designed as emergency action plans providing life-saving rather than day to day 186 
or preventative advice and all instruct to summon further professional help during a reaction. 187 
Presence of recommended components 188 
The two plans that contained the largest number of recommended components were both 189 
designed for institutions. This may reflect that it easier to include all the recommendations 190 
when the target environment for use is limited and defined (e.g. within a school).  191 
Alternatively, it may indicate that plans for individuals consider some of these 192 
recommendations irrelevant in an emergency – for example review dates of medication doses. 193 
The plans we identified overwhelmingly focussed on emergency management rather than day 194 
to day management.  Previously recommended components such as including the number of 195 
AAIs to carry may be more suited to everyday management plans than emergency 196 
management plans. 197 
It was not possible to assess whether for drug allergies both generic and proprietary names 198 
were recorded along with any cross sensitivities (as recommended), as these would be filled 199 
in at the time of the plans completion rather than printed onto the template.  However, it was 200 
noted that no plans included instructions to record this level of detail.  Indeed, no identified 201 
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plan was published alongside supporting instructions for the person completing the 202 
document, although guidance may be provided within clinical settings. 203 
There is variation in which symptoms are mentioned for patients to identify anaphylaxis and 204 
also in the actions that patients are advised to take to treat anaphylaxis. However, most plans 205 
split responses into mild/moderate reactions and severe reactions.  Where this division is not 206 
made within plans, it is often because a publisher produces separate documents for 207 
mild/moderate and severe reactions.  The AMPs that contained two ‘pathways’ presented this 208 
information clearly within the space constraints.  There is broad agreement as to which 209 
symptoms are considered severe, with particular attention given to respiratory and 210 
cardiovascular effects. 211 
Discrepancies between plans 212 
Several instructions or statements were included in a very small proportion of plans.  Three 213 
gave the option or recording allergens that a patient is “severely” reactive to.   These plans 214 
instructed patients who may have been exposed to these allergens to inject adrenaline even 215 
if not symptomatic.  Similarly, two plans advised AAI use for more than one symptom they 216 
considered minor.  The evidence base for these recommendations was not immediately clear. 217 
Recommendations for future plans 218 
By comparing the AMPs already in print in addition to the literature surrounding the topic we 219 
are able to suggest important features that are not widely published in existing AMPs. 220 
As discussed previously, most of the plans identified in the study time frame contain less than 221 
half of the features agreed as important by a consensus of experts in the field.  When revising 222 
plans, publishers should be aware of this research and consider whether it is possible to 223 
include more of the components whilst maintaining a document that is easy for patients and 224 
bystanders to read in a crisis.  225 
Plans should include brand specific instructions on how to use their AAI. This may reduce the 226 
number of patients using incorrect technique for their AAI despite prior training, 84% of 102 227 
patients in a 2015 study.(7)  Similarly, few plans instructed patients to always carry their AAI. 228 
This may be attributed to publishers considering this behaviour to be common sense. 229 
However, several case series exist indicating that in fatal episodes of anaphylaxis contributing 230 
factors included delay in adrenaline administration resulting from prescribed AAIs not being 231 
Page 9 
readily available.(8-11)  It is also known that overall rate of carriage of AAIs by adolescents is 232 
low, but having a written AMP improves adherence to self-care behaviours including the 233 
carriage of AAIs. (4) 234 
Plans currently give times to wait between doses as a range.  This  is to be expected given the 235 
paucity and low grade of evidence for the optimal gap between doses and reflects current 236 
guidelines from the World Allergy Organisation (WAO).(12, 13)  However, we suggest that giving 237 
a range introduces unnecessary ambiguity for lay-responders and that further research into 238 
this area may be beneficial. 239 
A greater focus should be given to patient positioning, which is a core element of first aid for 240 
any condition.  Plans should include the three instructions given in European and WAO 241 
guidelines for the emergency treatment of anaphylaxis.(12, 13)  Similarly, further attention may 242 
be beneficial for patients with co-morbid asthma.  These patients, particularly children, are at 243 
higher risk of death from anaphylaxis.(9, 10, 12)  This includes case reports where anaphylaxis has 244 
been confused with life threatening asthma.(14, 15)  Some plans clearly specified if the 245 
responder was unsure if the reaction was asthma or anaphylaxis to give the AAI, this is an 246 
instruction that could be included more widely. 247 
After the search period had concluded, a major new AMP was published by the American 248 
Academy of Pediatrics(16). This plan was a plan for individuals designed specifically for children.  249 
It contained no novel components that had not previously been identified in our review and 250 
included six of the components recommended by the e-Delphi study.  Like many other plans, 251 
it did not instruct patients on how to give an adrenaline injection.  This highlights that there 252 
are a wide range of institutions producing management plans and, despite new versions being 253 
released, there is little difference in their content.   254 
Limitations 255 
This study systematically identified and analysed anaphylaxis management plans, to identify 256 
both common and unique features within them. By using inclusive search criteria and the 257 
internet we identified 29 additional resources to those found in a previous study that confined 258 
its search to peer reviewed publications.(17) Inevitably not all AMPs will have been identified 259 
as others may only be available to clinicians on their institutional intranets, for example.  Our 260 
search methodology would also have not identified AMPs published in novel formats, for 261 
example smartphone apps that allow patients to create their own personalised treatment plan 262 
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by answering questions. The eDelphi consensus findings used as a ‘gold standard’ in this study 263 
was derived from experts from the UK and Ireland only, it would have been preferable if the 264 
‘gold standard’ had been derived from panellists working internationally.    265 
 266 
Further research  267 
To date there have been no randomised control trials demonstrating the overall effectiveness 268 
of anaphylaxis management plans (AMPs).(18) This is in contrast to the personalised 269 
management plans recommended in guidelines for asthma, which is supported by extremely 270 
strong (Grade A) evidence. (19)    In both adults and children, having a written management plan 271 
for asthma has been shown to reduce hospital admissions and minimize the effect of 272 
symptoms on daily living.(20-22)  The evidence has been pooled in a  meta-analysis to identify 273 
which individual components of these  plans provide the most benefit to patients with asthma. 274 
(23) 275 
This study provides a comprehensive assessment of the components and design of AMPs 276 
published in the English language.  This overview highlights to practitioners the variation 277 
between plans and encourages them to consider the individual patient’s needs and seek a 278 
plan that is best suited for them. 279 
Improving the content of management plans for anaphylaxis has to date focused on the 280 
preferences of allergy specialists.  However, we also need to be attentive to patients’ opinions 281 
also, and so co-design activities are needed.  Combining these two perspectives using co-282 
design methodology would bring us closer to the ‘optimal’ management plan.   The need for 283 
formal evaluation of AMPs is controversial; previous calls for a randomised control trial of 284 
management plans in anaphylaxis have not been universally supported.   Some argue that 285 
AMPs are such a low cost and low risk intervention, that research endeavours in this area are 286 
an unnecessary use of research time and funding.  Furthermore, as anaphylaxis is a potentially 287 
fatal condition there are significant ethical questions raised should the comparator be no 288 
management plan.(22) Conversely it can be argued that current best practice already includes 289 
the provision of an AMP but adherence to self-care behaviours remain very poor, and so 290 
studying interventions that improve self-management are worthy of attention.  The best way 291 
forward would be the design and evaluation of complex interventions, combining the AMP 292 
with patient education and/or allocation of an anaphylaxis buddy and/or membership of a 293 
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patient support organization.  With several interacting components, one design a preference 294 
trial or a randomized consent trial.  295 
Page 12 
 296 
References 297 
 298 
1. Simons FE, Clark S, Camargo CA, Jr. Anaphylaxis in the community: learning from the 299 
survivors. J Allergy Clin Immunol. 2009;124(2):301-6. 300 
2. Ewan PW, Clark AT. Efficacy of a management plan based on severity assessment in 301 
longitudinal and case-controlled studies of 747 children with nut allergy: proposal for 302 
good practice. Clin Exp Allergy. 2005;35(6):751-6. 303 
3. Clark AT, Ewan PW. Good prognosis, clinical features, and circumstances of peanut and 304 
tree nut reactions in children treated by a specialist allergy center. J Allergy Clin 305 
Immunol. 2008;122(2):286-9. 306 
4. Jones CJ, Llewellyn CD, Frew AJ, Du Toit G, Mukhopadhyay S, Smith H. Factors 307 
associated with good adherence to self-care behaviours amongst adolescents with 308 
food allergy. Pediatr Allergy Immunol. 2015;26(2):111-8. 309 
5. Worth A, Nurmatov U, Sheikh A. Key components of anaphylaxis management plans: 310 
consensus findings from a national electronic Delphi study. JRSM Short Reports. 311 
2010;1(5):42. 312 
6. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: 313 
The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction 314 
Grading System. J Allergy Clin Immunol. 2010;125(3):569-74, 74 e1-74 e7. 315 
7. Bonds RS, Asawa A, Ghazi AI. Misuse of medical devices: a persistent problem in self-316 
management of asthma and allergic disease. Ann Allergy Asthma Immunol. 317 
2015;114(1):74-6 e2. 318 
8. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. 319 
Clin Exp Allergy. 2000;30(8):1144-50. 320 
9. Xu YS, Kastner M, Harada L, Xu A, Salter J, Waserman S. Anaphylaxis-related deaths in 321 
Ontario: a retrospective review of cases from 1986 to 2011. Allergy Asthma Clin 322 
Immunol. 2014;10(1):38. 323 
10. Munoz-Furlong A, Weiss CC. Characteristics of food-allergic patients placing them at 324 
risk for a fatal anaphylactic episode. Current allergy and asthma reports. 2009;9(1):57-325 
63. 326 
11. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to 327 
foods. J Allergy Clin Immunol. 2001;107(1):191-3. 328 
12. Simons FE, Ardusso LR, Bilo MB, El-Gamal YM, Ledford DK, Ring J, et al. World allergy 329 
organization guidelines for the assessment and management of anaphylaxis. The 330 
World Allergy Organization journal. 2011;4(2):13-37. 331 
13. Muraro A, Roberts G, Worm M, Bilo MB, Brockow K, Fernandez Rivas M, et al. 332 
Anaphylaxis: guidelines from the European Academy of Allergy and Clinical 333 
Immunology. Allergy. 2014;69(8):1026-45. 334 
14. Rainbow J, Browne GJ. Fatal asthma or anaphylaxis? Emerg Med J. 2002;19(5):415-7. 335 
15. Sargant N, Erlewyn-Lajeunesse M, Benger J. Does anaphylaxis masquerade as asthma 336 
in children? Emerg Med J. 2015;32(1):83-4. 337 
16. American Academy of Pediatrics. Allergy and anaphylaxis emergency plan [online]. 338 
2017 [Available from: https://www.aap.org/en-us/Documents/AA-339 
EmergencyPlan.pdf]. 340 
17. Nurmatov U, Worth A, Sheikh A. Anaphylaxis management plans for the acute and 341 
long-term management of anaphylaxis: A systematic review. J Allergy Clin Immunol. 342 
2008;122(2):353-61.e3. 343 
Page 13 
18. Choo K, Sheikh A. Action plans for the long-term management of anaphylaxis: 344 
systematic review of effectiveness. Clin Exp Allergy. 2007;37(7):1090-4. 345 
19. British Thoracic Society Scottish Intercollegiate Guidelines N. British Guideline on the 346 
Management of Asthma. Thorax. 2008;63 Suppl 4:iv1-121. 347 
20. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, et al. Self-348 
management education and regular practitioner review for adults with asthma. The 349 
Cochrane database of systematic reviews. 2003(1):CD001117. 350 
21. Bhogal S, Zemek R, Ducharme FM. Written action plans for asthma in children. The 351 
Cochrane database of systematic reviews. 2006(3):CD005306. 352 
22. Zemek RL, Bhogal SK, Ducharme FM. Systematic review of randomized controlled trials 353 
examining written action plans in children: what is the plan? Arch Pediatr Adolesc Med. 354 
2008;162(2):157-63. 355 
23. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the 356 
key components. Thorax. 2004;59(2):94-9. 357 
24. Simons FE. Pharmacologic treatment of anaphylaxis: can the evidence base be 358 
strengthened? Curr Opin Allergy Clin Immunol. 2010;10(4):384-93 359 
 360 
  361 
Page 14 
Table i: Prevalence of customisation options within plans for individuals only 362 
Item Number of plans including 
item  (n,%) 
Full name of the patient 32 100% 
List of known allergens 32 100% 
Contact details for emergencies 30 94% 
Plan signed by doctor 27 84% 
Date that plan was completed 26 81% 
Date of birth 22 69% 
Photograph of patient 21 66% 
Plan signed by parent 14 44% 
Contact details for doctor 14 44% 
Weight 8 25% 
Plan signed by school representative 4 13% 
Name of class or teacher 4 13% 
Planned review or expiry date of plan 3 9% 
List of allergens extremely reactive to 3 9% 
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Table ii: Advice given before anaphylaxis occurs 366 
Recorded characteristic Number of plans including 
characteristic (n, %) 
Instruction to carry auto injector at all 
times 
7 17% 
Advice to inform close contacts about the 
existence of the plan 
6 15% 
Instruction to avoid known triggers 4 10% 
Instruction to wear medic alert bracelet or 
similar 
4 10% 
Instruction to carry more than one auto-
injector 
3 7% 
 367 
 368 
  369 
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Table iii: Prevalence of actions to take  370 
 371 
Recorded characteristic Number of plans including 
characteristic (n, %) 
Phone ambulance 41 100% 
Contact family or emergency contact 39 95% 
Give auto injector 38 93% 
Ambulance phone number for territory 38 93% 
Give further dose of adrenaline if no response 30 73% 
Stay with patient 25 61% 
Lay patient flat 24 59% 
Transport to hospital for ongoing observation 22 54% 
Give antihistamines 21 51% 
Words to the effect of "if in doubt, give the auto injector" 17 41% 
If breathing is difficult allow to sit 15 37% 
Call for help (audibly to attract nearby people rather than by phone) 14 34% 
Give other medications with space for medications to be entered (excluding 
specific asthma medications or antihistamines) 
12 29% 
Do not allow to stand or walk 12 29% 
Locate auto-injector 11 27% 
Recommendation for length of time to be observed in hospital 11 27% 
Start CPR if unresponsive or abnormally breathing 10 24% 
Words to the effect of "do not depend on antihistamines" 7 17% 
Remove insect stings by flicking 4 10% 
Do not remove ticks 3  7% 
Stay calm 2 5% 
 372 
 373 
 374 
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 377 
Figure 1: Flow chart showing identification of sources 378 
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 Figure 2: Frequency of symptoms mentioned on the AMP and whether classified as mild or severe 382 
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Search Term Phrase 
1 Allergy 
2 Anaphylaxis 
3 Food allergy 
4 Anaphylaxis management plan 
5 Adrenaline auto-injector 
Inclusion criteria Exclusion Criteria 
Website title or description relevant to initial search 
terms 
Website title/description describes a veterinary page 
Website title and description in English language 
Website title/description describes an online shop-
front or retailer 
 
Website tittle/description clearly irrelevant to initial 
search terms 
 385 
Table OR1: Search strategy employed to locate management plans 386 
 387 
  388 
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OR2: List of AMPs identified 389 
ID Publisher 
Title 
Country 
of 
Origin 
Organisation 
Type 
Publication 
or revision 
date 
(where 
specified) 
Number 
of  
recomm
ended 
compon
ents 
included 
Available from URL 
1 Allergic 
Reaction 
Toolkit 
United 
States 
Charity, NGO - 5 https://www.allergicreactiontoolkit.com/-
/media/allergic%20reaction%20toolkit/files/anaphylaxis_emergency_care_plan.p
df 
2 Allergy 
Asthma 
Information 
Association 
Canada Charity, NGO 2014 1 http://www.aaia.ca/en/anaphylaxis_brochure_en.pdf 
3 Allergy 
South Africa 
South 
Africa 
Charity, NGO - 4 http://www.mm3admin.co.za/documents/docmanager/8e7be0a4-2b8d-453f-
875e-cd1e5132b829/00035820.pdf 
4 American 
Academy of 
Allergy 
Asthma and 
Immunology 
United 
States 
Charity, NGO 2013 4 http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Libraries/
Anaphylaxis-Emergency-Action-Plan.pdf 
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ID Publisher 
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Country 
of 
Origin 
Organisation 
Type 
Publication 
or revision 
date 
(where 
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of  
recomm
ended 
compon
ents 
included 
Available from URL 
5 Anaphylaxis 
Ireland 
Republic 
of 
Ireland 
Charity, NGO - 4 http://www.anaphylaxisireland.ie/wp-content/uploads/2013/01/MCC-
broc_web_revDec12-3.pdf 
6 Anaphylaxis 
Ireland 
Republic 
of 
Ireland 
Charity, NGO - 4 http://www.anaphylaxisireland.ie/wp-content/uploads/2013/01/MCC-
broc_web_revDec12-3.pdf 
7 Anaphylaxis 
Netherlands 
Other Charity, NGO 2015 6 Provided directly by author via email 
8 Asthma and 
Allergy 
Foundation 
of America 
United 
States 
Charity, NGO - 4 http://www.aafa.org/media/Child-Care-Asthma-Allergy-Action-Card.pdf 
9 Asthma and 
Allergy 
Foundation 
of America 
United 
States 
Charity, NGO - 5 http://www.aafa.org/media/Anaphylaxis-Emergency-Action-Plan.pdf 
10 Asthma, 
Allergy & 
Sinus Center 
United 
States 
Primary or 
secondary 
healthcare 
provider 
- 5 http://paallergy.com/assets/anaphylaxis-treatment.pdf 
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of 
Origin 
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Publication 
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of  
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Available from URL 
11 Australasian 
Society of 
Clinical 
Immunology 
and Allergy 
Australia Charity, NGO 2015 7 http://www.allergy.org.au/images/stories/anaphylaxis/2015/ASCIA_Action_Plan_
Anaphylaxis_EpiPen_Personal_2015.pdf 
12 Australasian 
Society of 
Clinical 
Immunology 
and Allergy 
Australia Charity, NGO 2015 6 http://www.allergy.org.au/images/stories/anaphylaxis/2015/ASCIA_Action_Plan_
Allergic_Reactions_2015.pdf 
13 Australasian 
Society of 
Clinical 
Immunology 
and Allergy 
Australia Charity, NGO 2015 3 http://www.allergy.org.au/images/stories/anaphylaxis/2015/ASCIA_Action_Plan_
Anaphylaxis_EpiPen_General_2015.pdf 
14 Be Allergy 
Aware 
Republic 
of 
Ireland 
Charity, NGO - 1 http://www.beallergyaware.com/upload/Understanding%20Anaphylaxis%20Leafl
et.pdf 
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of  
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ents 
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Available from URL 
15 British 
Columbia 
School 
Trustees 
Association 
Canada Educational 
body/school 
2010 4 https://dsweb.bcsta.org/docushare/dsweb/Get/Document-
33393/Sample%20Anaphylactic%20Student%20Emergency%20Procedure%20Pla
n%20-%20June%202010.doc 
16 British 
Society for 
Allergy and 
Clinical 
Immunology 
United 
Kingdom 
Charity, NGO 2013 5 http://www.bsaci.org/LiteratureRetrieve.aspx?ID=123699 
17 British 
Society for 
Allergy and 
Clinical 
Immunology 
United 
Kingdom 
Charity, NGO 2013 4 http://www.bsaci.org/LiteratureRetrieve.aspx?ID=123701 
18 British 
Society for 
Allergy and 
Clinical 
Immunology 
United 
Kingdom 
Charity, NGO 2013 5 http://www.bsaci.org/LiteratureRetrieve.aspx?ID=123700 
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Publication 
or revision 
date 
(where 
specified) 
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included 
Available from URL 
19 British 
Society for 
Allergy and 
Clinical 
Immunology 
United 
Kingdom 
Charity, NGO 2014 5 http://www.bsaci.org/LiteratureRetrieve.aspx?ID=127070 
20 Californian 
School 
Nurse 
Association 
United 
States 
Educational 
body/school 
- 5 http://www.csno.org/uploads/1/7/2/4/17248852/anaphalaxis_tx_procedures-
revised_4.doc 
21 Canadian 
inter agency 
group 
Canada Charity, NGO 2014 4 http://www.aaia.ca/en/Anaphylaxis_Emergency_Plan_with_EpiPen_instructions.
pdf 
22 Canadian 
inter agency 
group 
Canada Charity, NGO 2014 4 http://www.aaia.ca/en/Anaphylaxis_Emergency_Plan_with_Allerject_instructions
.pdf 
23 Epi Pen United 
Kingdom 
Pharmaceutical 
company 
2012 5 http://www.epipen.co.uk/docs/FINAL_234423_EpiPen-action-plan-
NGA_070912.pdf 
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Publication 
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ents 
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Available from URL 
24 Food Allergy 
Research 
Education 
United 
States 
Charity, NGO 2014 4 http://www.foodallergy.org/document.doc?id=234 
25 Foods 
Matter 
United 
Kingdom 
Charity, NGO - 2 http://www.foodsmatter.com/allergy_intolerance/management_all_in_school/ar
ticles/waggott-severe-allergy-summary.pdf 
26 Foods 
Matter 
(Individual 
Contribution) 
United 
Kingdom 
Private individual - 2 http://www.foodsmatter.com/allergy_intolerance/anaphylaxis/articles/anaphyla
xis_action_plan.pdf 
27 Guy's and St 
Thomas' 
NHS Trust 
United 
Kingdom 
Primary or 
secondary 
healthcare 
provider 
2011 4 http://www.allergyacademy.org/sites/default/files/resources_uploads/Child_pla
n1_for_allergic_reactions.pdf 
28 Guy's and St 
Thomas' 
NHS Trust 
United 
Kingdom 
Primary or 
secondary 
healthcare 
provider 
2011 4 http://www.allergyacademy.org/sites/default/files/resources_uploads/Child_pla
n2_for_allergic_reactions.pdf 
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29 Guy's and St 
Thomas' 
NHS Trust 
United 
Kingdom 
Primary or 
secondary 
healthcare 
provider 
2009 4 http://www.allergyacademy.org/sites/default/files/resources_uploads/Child_pla
n3_for_allergic_reactions_0.pdf 
30 Halton 
Region 
School 
Board 
Canada Educational 
body/school 
- 3 http://www.hdsb.ca/ParentInfo/Health%20Protocols/AnaphylaxisProtocol.pdf 
31 Harrogate 
District NHS 
Trust 
United 
Kingdom 
Primary or 
secondary 
healthcare 
provider 
2011 5 http://www.staidans.co.uk/wp-
content/uploads/2014/12/adrenaline_action_plan.pdf 
32 Illinois State 
Board of 
Education 
United 
States 
Educational 
body/school 
- 8 http://www.isbe.net/nutrition/pdf/food_allergy_guidelines.pdf 
33 Irish Food 
Allergy 
Network 
Republic 
of 
Ireland 
Charity, NGO - 6 http://ifan.ie/wp-content/uploads/2013/06/Safety-Plan.pdf 
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34 IWK 
Healthcare 
Canada Charity, NGO 2013 3 http://www.iwk.nshealth.ca/sites/default/files/PL-0259-Eng-and-FR-DONE-Mar1-
2013.pdf 
35 Mary H 
Weiser Food 
Allergy 
Center 
Canada Primary or 
secondary 
healthcare 
provider 
2013 6 http://medicine.umich.edu/sites/default/files/content/downloads/FAAP%20UM
%204_2014.pdf 
36 Mission 
Public 
Schools 
Canada Educational 
body/school 
2009 3 http://www.mpsd.ca/districtinformation/pdf/procs/AP101-Emergency_Plan.pdf 
37 National 
Association 
of School 
Nurses 
United 
States 
Educational 
body/school 
2011 2 https://www.nasn.org/portals/0/resources/faat_no_ECP.pdf 
38 National 
Institute of 
Health and 
Disease 
United 
States 
Charity, NGO - 5 http://www.niaid.nih.gov/topics/foodallergy/clinical/documents/faguidelinespati
ent.pdf 
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39 Northcott Australia Care/Community 
organisation 
- 9 https://www.northcott.com.au/sites/default/files/Anaphylaxis%20Management
%20Plan.pdf 
40 Prince 
Edward 
Island 
Canada Care/Community 
organisation 
- 3 http://www.gov.pe.ca/photos/original/anasept_2006.pdf 
41 Winnipeg 
Regional 
Health 
Authority 
Canada Public 
health/regional 
health body 
2012 3 http://www.pembinatrails.ca/lindenmeadows/Staff/Anaphylaxis%20Handout%20
2012-04-01.pdf 
 390 
 391 
  392 
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OR3: Table cross-referencing recommended components (over 80% agreement of a 
panel of 24 UK/Irish experts) with the plans that contain them 
Recorded characteristic ID Number of plans that contain 
characteristic (see table OR2) 
Contact details for emergencies 1, 3-4, 7-12, 15-19, 21-24, 26-33, 35-36, 38-
39 
Details of known allergens 1, 3-12, 15-19, 21-24, 27-33, 35-36, 38-40 
How to recognise and respond to mild, 
moderate and severe allergic reactions 
1, 3, 5-7, 11-13, 16-20, 23-25, 27-29, 31-35, 
37, 39 
List of medication prescribed and 
instructions on when to use it 
1, 4, 7-12, 32, 35, 38-39 
Clear statement of the need to administer 
adrenaline without hesitation 
5-7, 9, 11, 13, 16, 18-20, 31-34, 38-39, 41 
Instructions to call the emergency services All 
Location where medication is stored 15, 20-23, 32-33, 39-41 
Review dates of medication doses (recorded 
as option to give the plan an expiry date) 
11-12, 39 
Number of AAIs to carry 10, 20, 35 
Who is trained to give medication in the 
patient’s location 
32, 39 
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 OR FIG1: Prevalence of AAI instructions by brand 
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